Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (September 2026)
28 slides from Maat Pharma's investor presentation, September 2026
Slide 1: Boosting Survival Through Innovative Immune Modulation
Boosting Survival Through Innovative Immune Modulation September 2026
Slide 2: Disclaimer
MaaT Pharma September 2026 2 Disclaimer This document has been prepared by MaaT Pharma (the "Company") The information contained in this document has not been subject to This document contains certain forward-looking statements. These and is for information and background purposes only. independent
Slide 3: Company Overview
Company Overview
Slide 4: MaaT Pharma: A Clinical-Stage Company with a Differentiated Oncology Platform
MaaT Pharma September 2026 4 MaaT Pharma: A Clinical-Stage Company with a Differentiated Oncology Platform Clinical proof of concept in Multi-Assets Oncology Potential expansion into hemato-oncology Platform immuno-oncology ARES trial met its primary endpoint. ARES SAT MET-N Standardized, donor-deri
Slide 5: Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes
MaaT Pharma September 2026 5 Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings STARTING POINT EXPECTED BENEFITS Xervyteg® (MaaT013) Dysbiosis Resolution Control of inflammation and of aGvHD restoration of gut integrity Restoration of Loss of
Slide 6: Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma September 2026 6 Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates Native Ecosystem Co-cultured Ecosystem cGMP Manufacturing Facility Xervyteg® (MaaT013) 11,000 MaaT034 1,300,000 MaaT033 MaaT03X Up to 300,000 Donor stool MET-N / MET-C Screening for target profile PROPR
Slide 7: A Diversified Pipeline with Clinical-Stage Assets
MaaT Pharma September 2026 7 A Diversified Pipeline with Clinical-Stage Assets Indication Program Indication PRCL Ph. 1 Ph. 2 Ph. 3 Current Status Recent or Upcoming milestones Subject to appropriate Negative CHMP opinion following ARES completed, PHOENIX RCT Planned funding and regulatory re-examin
Slide 8: Xervyteg (MaaT013) in aGvHD
Xervyteg®(MaaT013) in aGvHD
Slide 9: Undeniable High Unmet Medical Need With No Approved Therapies
MaaT Pharma September 2026 9 Undeniable High Unmet Medical Need With No Approved Therapies Third-line refractory aGvHD, a rare disease with Treatment Paradigm in aGvHD high morbidity and substantial patient burden 1L treatment: High-dose Corticosteroids 2L treatment: Ruxolitinib (approved for SR-aGv
Slide 10: Treatment with Xervyteg (MaaT013) restores eubiosis and key microbiome functions
MaaT Pharma September 2026 10 Treatment with Xervyteg® (MaaT013) restores eubiosis and key microbiome functions associated with durable clinical response Clinical data demonstrates Xervyteg® (MaaT013) engrafts Preclinical and clinical data show Xervyteg® (MaaT013) and drives positive microbiome chan
Slide 11: ARES in aGvHD in 3L: Primary Endpoint Met with Significant Day-28 GI-ORR
MaaT Pharma September 2026 11 ARES in aGvHD in 3L: Primary Endpoint Met with Significant Day-28 GI-ORR; Responses Sustained Through Month 3 Response Rate (n=67) Key Takeaways Gastrointestinal overall All-organ overall response (%) response (%) Primary 80 80 8080 Endpoint Met 61.2 with Significant Re
Slide 12: ARES: Higher Observed Overall Survival vs Best Available Therapy (BAT) in 3L
MaaT Pharma September 2026 12 ARES: Higher Observed Overall Survival vs Best Available Therapy (BAT) in 3L CHRONOS: real world outcomes in CS- and n=59 ARES: pivotal study outcomes in CS- and n=66 ruxolitinib-refractory GI-aGvHD ruxolitinib-refractory GI-aGvHD (n=66) Overall Survival(OS) (%) Overall
Slide 13: PHOENIX: Planned Global Randomized Phase 3 Study
MaaT Pharma September 2026 13 PHOENIX: Planned Global Randomized Phase 3 Study Trial population PHOENIX study (n=138) Subject to appropriate funding and regulatory clearance Key inclusion criteria Timelines (expected) Xervyteg® (MaaT013) D28 Follow-up (D29 to D365) • Adult aGvHD patients grade II to
Slide 14: Early Access Program Shows an Increasing International Demand from Physicians
MaaT Pharma September 2026 14 Early Access Program Shows an Increasing International Demand from Physicians Number of authorizations Clinical Outcomes (Real World Evidence) 156 160 +18% 135 • 173 GvHD patients analyzed as of October 2024 and 140 +24% presented at EHA 2025: 120 109 • Efficacy (All li
Slide 15: MaaT033 in allo-HSCT
MaaT033 in allo-HSCT
Slide 16: PHOEBUS (MaaT033) - Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study in Allo-HSCT
MaaT Pharma September 2026 16 PHOEBUS (MaaT033) - Phase 2b, Randomized (1:1), Double-Blind, Placebo-Controlled Study in Allo-HSCT PHOEBUS Trial flow chart 388 Pre Allo-HSCT Post Allo-HSCT patients treatment phase Allo-HSCT Follow up treatment phase 59 D-21 D-7 D+21 M+3 M+12 sites Visit 1 Visit 2 Vis
Slide 17: MaaT034: Unlocking The Full Potential of Immunotherapy Through The Microbiome
MaaT034: Unlocking The Full Potential of Immunotherapy Through The Microbiome
Slide 18: Primary Resistance to ICIs: A Major Unmet Need for Patient with Advanced Cancers
MaaT Pharma September 2026 18 Primary Resistance to ICIs: A Major Unmet Need for Patient with Advanced Cancers High Unmet Medical Need Approximately 19 million new cancer cases are 01 diagnosed worldwide each year. Lung Cancer Skin Cancer (NSCLC) (Melanoma) Immune Checkpoint Inhibitors (ICI) have si
Slide 19: The microbiome, a Promising Therapeutic Target in Immuno-Oncology
MaaT Pharma September 2026 19 The microbiome, a Promising Therapeutic Target in Immuno-Oncology With a Deep Biological Rationale Microbiome is associated with ICI response • Microbiome diversity tracks with ICI response across solid tumors; antibiotic- and chemo-driven dysbiosis predicts non- respon
Slide 20: Novel Microbiome Therapeutic in Immuno-Oncology Built on Clinical and Manufacturing Expertise
MaaT Pharma September 2026 20 Novel Microbiome Therapeutic in Immuno-Oncology Built on Clinical and Manufacturing Expertise in Microbiome Ecosystem Therapies (MET) MET-N — STANDARDIZED, DONOR-DERIVED AACR 2025 Reproducible products, late-stage clinical data in hemato-oncology 61.2% Pooled-donor, hig
Slide 21: MET-C: a Scalable and Innovative Platform for Generating Reproducible Complex Microbiotherapies
MaaT Pharma September 2026 21 MET-C: a Scalable and Innovative Platform for Generating Reproducible Complex Microbiotherapies AI-defined microbiota features associated with ICI response Scalable, demand-driven manufacturing enabled by co-cultured technology Donor stool Consistent batches: >80% speci
Slide 22: Preclinical Data Demonstrate MaaT034 Shows Properties Associated with Microbiome Potentiation of ICI Response
MaaT Pharma September 2026 22 Preclinical Data Demonstrate MaaT034 Shows Properties Associated with Microbiome Potentiation of ICI Response MaaT034 (yellow in all figures) Engrafts and produces immunomodulatory Restores gut barrier integrity and reduces Activates immune response metabolites in germ-
Slide 23: MaaT034 Enhances Anti-Tumor Efficacy of Anti-PD-1 Therapy in Germ-Free Mice
MaaT Pharma September 2026 23 MaaT034 Enhances Anti-Tumor Efficacy of Anti-PD-1 Therapy in Germ-Free Mice Preclinical Proof of Concept Tumor growth Survival germ-free 100 200 Tumor Volume (mm3) anti-PD1 Survival rate (%) MaaT034 75 150 MaaT034 + anti-PD1 * 50 100 germ-free Anti-PD-1 anti-PD1 50 * 25
Slide 24: A Unique Innovation with a Potential Path to Clinical Validation
MaaT Pharma September 2026 24 A Unique Innovation with a Potential Path to Clinical Validation Built on MET-N Innovation Unique & scalable Regulatory: Multiple value learnings FDA-first strategy inflection points 10+ years of scientific, AI-enabled functional Donor-independent Pre-IND CMC-focused CM
Slide 25: Upcoming Milestones
Upcoming Milestones
Slide 26: Upcoming Milestones
MaaT Pharma September 2026 26 Upcoming Milestones * Subject to appropriate funding and regulatory clearance. Program Current status Next operational step Potential milestone Xervyteg® (MaaT013)/ Funding and regulatory Potential FPI H1 2027 in the Phase 3 RCT preparation* PHOENIX clearance U.S. and R
Slide 27: Corporate Social Responsibility
MaaT Pharma September 2026 27 Corporate Social Responsibility MaaT Pharma is a leading, late-stage clinical Patients are the priority. MaaT Pharma is committed → Innovate and raise awareness to deliver Company committed to advancing gut to patients and to the protection of human health by better car
Slide 28: Thank you
Thank you